Literature DB >> 6337700

Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder.

H W Herr, C M Pinsky, W F Whitmore, H F Oettgen, M R Melamed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6337700     DOI： 10.1002/1097-0142(19830401)51:7<1323::aid-cncr2820510724>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  18 in total

Review 1.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

2.  Topical anaesthesia for bladder biopsies and cautery: intravesical lidocaine versus caudal anaesthesia.

Authors:  T Amano; M Ohkawa; K Kunimi; Y Oshinoya; T Uchibayashi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 3.  Invasive bladder cancer--possible future treatment considerations.

Authors:  R A Gardiner
Journal:  Urol Res       Date:  1986

Review 4.  Intravesical chemotherapy in the United States. An overview.

Authors:  J T Spaulding
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder.

Authors:  A P vd Meijden; P A Steerenberg; W H de Jong; M J Bogman; W F Feitz; B T Hendriks; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1986

6.  Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients.

Authors:  P Conti; M Reale; M Nicolai; R C Barbacane; F C Placido; R Iantorno; R Tenaglia
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

7.  Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin.

Authors:  J S Shin; J H Park; J D Kim; J M Lee; S J Kim
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

8.  Purification of a mycobacterial adhesin for fibronectin.

Authors:  T L Ratliff; R McCarthy; W B Telle; E J Brown
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Phase I/II trial of intravesical methotrexate for superficial bladder tumors.

Authors:  C N Sternberg; A Yagoda; N H Bander; W F Whitmore; J L Huffman; M Fleisher; M Melamed; M P Fanucchi; P Hollander; E D Vaughan
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.